Switch theme
Sign up to access all valuation multiples
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
2001
24
LTM Revenue $5K
LTM EBITDA -$23.6M
$58.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Genelux has a last 12-month revenue (LTM) of $5K and a last 12-month EBITDA of -$23.6M.
In the most recent fiscal year, Genelux achieved revenue of $8K and an EBITDA of -$29.0M.
Genelux expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Genelux valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5K | XXX | $8K | XXX | XXX | XXX |
| Gross Profit | $5K | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$23.6M | XXX | -$29.0M | XXX | XXX | XXX |
| EBITDA Margin | -502925% | XXX | -362075% | XXX | XXX | XXX |
| EBIT | -$32.8M | XXX | -$31.7M | XXX | XXX | XXX |
| EBIT Margin | -698444% | XXX | -396200% | XXX | XXX | XXX |
| Net Profit | -$31.4M | XXX | -$29.9M | XXX | XXX | XXX |
| Net Margin | -670166% | XXX | -373362% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Genelux's stock price is $2.
Genelux has current market cap of $91.9M, and EV of $58.6M.
See Genelux trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $58.6M | $91.9M | XXX | XXX | XXX | XXX | $-0.94 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Genelux has market cap of $91.9M and EV of $58.6M.
Genelux's trades at 7321.2x EV/Revenue multiple, and -2.0x EV/EBITDA.
Equity research analysts estimate Genelux's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Genelux has a P/E ratio of -2.9x.
See valuation multiples for Genelux and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $91.9M | XXX | $91.9M | XXX | XXX | XXX |
| EV (current) | $58.6M | XXX | $58.6M | XXX | XXX | XXX |
| EV/Revenue | 12487.1x | XXX | 7321.2x | XXX | XXX | XXX |
| EV/EBITDA | -2.5x | XXX | -2.0x | XXX | XXX | XXX |
| EV/EBIT | -1.8x | XXX | -1.8x | XXX | XXX | XXX |
| EV/Gross Profit | 12487.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.9x | XXX | -3.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGenelux's last 12 month revenue growth is 23271%
Genelux's revenue per employee in the last FY averaged $0K, while opex per employee averaged $1.3M for the same period.
Genelux's rule of 40 is 7709% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Genelux's rule of X is -444747% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Genelux and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 23271% | XXX | 1720% | XXX | XXX | XXX |
| EBITDA Margin | -502925% | XXX | -362075% | XXX | XXX | XXX |
| EBITDA Growth | -1% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 7709% | XXX | -338804% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -444747% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 237475% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 396300% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genelux acquired XXX companies to date.
Last acquisition by Genelux was XXXXXXXX, XXXXX XXXXX XXXXXX . Genelux acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Genelux founded? | Genelux was founded in 2001. |
| Where is Genelux headquartered? | Genelux is headquartered in United States of America. |
| How many employees does Genelux have? | As of today, Genelux has 24 employees. |
| Who is the CEO of Genelux? | Genelux's CEO is Mr. Thomas Zindrick, J.D.. |
| Is Genelux publicy listed? | Yes, Genelux is a public company listed on NAS. |
| What is the stock symbol of Genelux? | Genelux trades under GNLX ticker. |
| When did Genelux go public? | Genelux went public in 2023. |
| Who are competitors of Genelux? | Similar companies to Genelux include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Genelux? | Genelux's current market cap is $91.9M |
| What is the current revenue of Genelux? | Genelux's last 12 months revenue is $5K. |
| What is the current revenue growth of Genelux? | Genelux revenue growth (NTM/LTM) is 23271%. |
| What is the current EV/Revenue multiple of Genelux? | Current revenue multiple of Genelux is 12487.1x. |
| Is Genelux profitable? | Yes, Genelux is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Genelux? | Genelux's last 12 months EBITDA is -$23.6M. |
| What is Genelux's EBITDA margin? | Genelux's last 12 months EBITDA margin is -502925%. |
| What is the current EV/EBITDA multiple of Genelux? | Current EBITDA multiple of Genelux is -2.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
